CXCR2 and acute myeloid leukemia: In addition, CXCR1 and CXCR2 mRNA expression (median 9.17 ± 0.38 versus 6.15 ± 0.85, p < 0.001) in 533 AML patients (for details, see section 3.5), while highly correlated with each other (r = 0.43, p < 0.001 [Pearson]) had no impact on overall (Hazard ratios [HR]: CXCR1 0.91 [95 CI 0.68–1.21], CXCR2 HR 0.96 [0.84–1.09]) and relapse free survival (HR: CXCR1 0.96 [0.65–1.4], CXCR2 1.02 [0.87–1.21]).